The Efficacy of the Ribonucleotide Reductase Inhibitor Didox in Preclinical Models of AML

Acute Myeloid Leukemia (AML) is an aggressive malignancy which leads to marrow failure, and ultimately death. There is a desperate need for new therapeutics for these patients. Ribonucleotide reductase (RR) is the rate limiting enzyme in DNA synthesis. Didox (3,4-Dihydroxybenzohydroxamic acid) is a novel RR inhibitor noted to be more potent than hydroxyurea. In this report we detail the activity and toxicity of Didox in preclinical models of AML. RR was present in all AML cell lines and primary patient samples tested. Didox was active against all human and murine AML lines tested with IC50 values in the low micromolar range (mean IC50 37 µM [range 25.89–52.70 µM]). It was active against primary patient samples at concentrations that did not affect normal hematopoietic stem cells (HSCs). Didox exposure resulted in DNA damage and p53 induction culminating in apoptosis. In syngeneic, therapy-resistant AML models, single agent Didox treatment resulted in a significant reduction in leukemia burden and a survival benefit. Didox was well tolerated, as marrow from treated animals was morphologically indistinguishable from controls. Didox exposure at levels that impaired leukemia growth did not inhibit normal HSC engraftment. In summary, Didox was well tolerated and effective against preclinical models of AML.

[1]  G. Marcucci,et al.  RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia. , 2012, Blood.

[2]  T. Pardee Overexpression of MN1 Confers Resistance to Chemotherapy, Accelerates Leukemia Onset, and Suppresses p53 and Bim Induction , 2012, PloS one.

[3]  Santhosh K. P. Kumar,et al.  Didox, a ribonucleotide reductase inhibitor, induces apoptosis and inhibits DNA repair in multiple myeloma cells , 2006, British journal of haematology.

[4]  C. Mathews DNA precursor metabolism and genomic stability , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[5]  Asim Khwaja,et al.  Acute myeloid leukaemia , 2016, Nature Reviews Disease Primers.

[6]  Mansoor M Ahmed,et al.  Suppression of retrovirus-induced immunodeficiency disease (murine AIDS) by trimidox and didox: novel ribonucleotide reductase inhibitors with less bone marrow toxicity than hydroxyurea. , 2002, Antiviral research.

[7]  G. Ehninger,et al.  A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial. , 2010, Blood.

[8]  B. Quesnel,et al.  p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. , 1994, Blood.

[9]  J. Bigby Harrison's Principles of Internal Medicine , 1988 .

[10]  J. Dipersio,et al.  Bone Marrow Stromal Cells Modulate Mouse ENT1 Activity and Protect Leukemia Cells from Cytarabine Induced Apoptosis , 2012, PloS one.

[11]  A. Levitzki,et al.  Enhanced ROS Production in Oncogenically Transformed Cells Potentiates c-Jun N-Terminal Kinase and p38 Mitogen-Activated Protein Kinase Activation and Sensitization to Genotoxic Stress , 2001, Molecular and Cellular Biology.

[12]  C. Mayhew,et al.  In Vivo and In Vitro Comparison of the Short‐Term Hematopoietic Toxicity Between Hydroxyurea and Trimidox or Didox, Novel Ribonucleotide Reductase Inhibitors with Potential Anti‐HIV‐1 Activity , 1999, Stem cells.

[13]  T. Ishihara,et al.  Ribonucleotide Reductase Immunoreactivity in Adenocarcinoma Cells and Malignant or Reactive Mesothelial Cells in Serous Effusions , 2003, Acta Cytologica.

[14]  G. Nolan,et al.  Distinct Patterns of DNA Damage Response and Apoptosis Correlate with Jak/Stat and PI3Kinase Response Profiles in Human Acute Myelogenous Leukemia , 2010, PloS one.

[15]  C. Felix,et al.  The molecular basis of leukemia. , 2004, Hematology. American Society of Hematology. Education Program.

[16]  G. Peters,et al.  Activation of caspases and induction of apoptosis by novel ribonucleotide reductase inhibitors amidox and didox. , 2001, Experimental hematology.

[17]  R. Hills,et al.  A comparison of low‐dose cytarabine and hydroxyurea with or without all‐trans retinoic acid for acute myeloid leukemia and high‐risk myelodysplastic syndrome in patients not considered fit for intensive treatment , 2007, Cancer.

[18]  T. Naoe,et al.  Prognostic value of p53 gene mutations and the product expression in de novo acute myeloid leukemia , 2000, European journal of haematology.

[19]  M. Minden,et al.  Outcomes and quality of care in acute myeloid leukemia over 40 years , 2009, Cancer.

[20]  J. Downing,et al.  Mouse models of human AML accurately predict chemotherapy response. , 2009, Genes & development.

[21]  G. Vercellotti,et al.  Robust Vascular Protective Effect of Hydroxamic Acid Derivatives in a Sickle Mouse Model of Inflammation , 2006, Microcirculation.

[22]  M. Fukushima,et al.  Upregulation of Enzymes Metabolizing 5-Fluorouracil in Colorectal Cancer , 2006, Chemotherapy.

[23]  M. Grever,et al.  Phase I Study of GTI-2040, an Antisense to Ribonucleotide Reductase, in Combination with High-Dose Cytarabine in Patients with Acute Myeloid Leukemia , 2008, Clinical Cancer Research.

[24]  H. Kantarjian,et al.  The characteristics and outcome of patients with late relapse acute myelogenous leukemia. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Yujia Dai,et al.  ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia. , 2007, Blood.

[26]  E. Takeda,et al.  Role of ribonucleotide reductase in expression in the neoplastic program. , 1981, Life sciences.

[27]  Bob Löwenberg,et al.  Review Articles (434 articles) , 2008 .

[28]  F. Appelbaum,et al.  Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5). , 2001, Experimental hematology.

[29]  Tarik Tihan,et al.  Synergistic cytotoxicity of the ribonucleotide reductase inhibitor didox (3,4-dihydroxy-benzohydroxamic acid) and the alkylating agent carmustine (BCNU) in 9L rat gliosarcoma cells and DAOY human medulloblastoma cells , 2004, Cancer Chemotherapy and Pharmacology.

[30]  G. Wampler,et al.  New ribonucleotide reductase inhibitors with antineoplastic activity. , 1979, Cancer research.

[31]  J. G. Cory,et al.  Inhibitors of Ribonucleoside Diphosphate Reductase Activity , 1989 .

[32]  O. Oakley,et al.  Inhibition of allogeneic inflammatory responses by the Ribonucleotide Reductase Inhibitors, Didox and Trimidox , 2010, Journal of Inflammation.

[33]  K. Döhner,et al.  High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics. , 2006, Blood.

[34]  F. Ferrara,et al.  Prognostic factors and therapeutic options for relapsed or refractory acute myeloid leukemia. , 2004, Haematologica.

[35]  D. Kerr,et al.  A phase 1 and pharmacokinetic study of didox: a ribonucleotide reductase inhibitor. , 1988, British Journal of Cancer.

[36]  Li-ming Wang,et al.  Overexpression of catalytic subunit M2 in patients with ovarian cancer. , 2012, Chinese medical journal.

[37]  B. Quesnel,et al.  p53 Mutations Are Associated With Resistance to Chemotherapy and Short Survival in Hematologic Malignancies , 1994 .

[38]  V. Bergdall,et al.  Ribonucleotide reductase inhibitors reduce atherosclerosis in a double-injury rabbit model. , 2009, Comparative medicine.

[39]  Yi Ning,et al.  Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. , 2006, Blood.